Bristol Myers Squibb obtained an exclusive global license to Agenus' AGEN1777, a TIGIT-targeting bispecific antibody program. Agenus received $200M upfront and is eligible for up to $1.36B in development, regulatory and commercial milestones plus tiered double-digit royalties.
Key facts
AnnouncedMay 18, 2021
Deal value$1.6B
Deal typeLicensing/Option
Therapeutic areaSolid tumors including non-small cell lung cancer
IndicationsSolid tumors including non-small cell lung cancer